BUZZ-Zymeworks jumps after JPM upgrades stock to 'overweight'

Reuters12-16
BUZZ-Zymeworks jumps after JPM upgrades stock to 'overweight'

** Cancer therapy developer Zymeworks' ZYME.O shares up as much as 10.6% to $13.91

** Brokerage J.P.Morgan upgrades company's shares to "overweight" from "neutral", raises PT by $6 to $18

** Recent R&D day event has brokerage more confident in company's oncology and autoimmune diseases pipeline, with two distinct TCE, ADC cancer therapies progressing in the clinics - JPM

** Company's cancer drug Zani provides "solid support" to stock valuation - brokerage

** JPM believes 2025 is the year to pay attention and could begin to see one or more of company's "5x5" pipeline plan succeeding in clinics

** Zymeworks' internal portfolio is largely underappreciated at this level as it begins to take shape as a true "multiple shots on goal" story with attractive upside potential - brokerage

** Brokerage Jefferies also raises PT on company's shares by $2 to $24

** 6 of 8 brokerages rate the stock "buy" or higher, and 2 "hold"; median PT $18.75 - LSEG

** Including session moves, stock up 32% YTD

(Reporting by Neil J Kanatt in Bengaluru)

((Neil.JKanatt@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment